Clinical trial
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients…
NCT00171860 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00171860 |
|---|---|
| Title | A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome |
| Official title | A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypereosinophilic Syndrome |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 24 |
| Start date | Sep 1, 2002 |
| Primary completion | Jul 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | May 1, 2012 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: